Margarida Maia, PhD,  science writer—

Ofev (nintedanib) more than halved the rate of lung function decline in patients who developed interstitial lung disease (ILD) associated with rheumatoid arthritis (RA), an inflammatory disease. That’s according to data from INBUILD (NCT02999178), a Phase 3 trial of more than 650 adults with progressive fibrosing ILDs in…

A Phase 3 trial of pamrevlumab, an experimental therapy from FibroGen to treat idiopathic pulmonary fibrosis (IPF), failed to meet its primary goal of slowing lung function decline. General safety and tolerability were seen in treated patients in ZEPHYRUS-1 (NCT03955146), which tested 48 weeks of pamrevlumab’s use…

Insilico Medicine made its entry into Phase 2 clinical testing with INS018_055, a small molecule it discovered and designed using artificial intelligence (AI), as a potential treatment for idiopathic pulmonary fibrosis (IPF). Patients have now received the first dose of oral INS018_055 in a randomized placebo-controlled Phase 2…

A new, potentially disease-specific imaging agent may one day allow doctors to identify pulmonary fibrosis (PF) in earlier stages, when the start of treatment can be more effective, according to a study in a mouse model of the disease. Called 64Cu-GPVI-Fc, the agent — coupled with positron emission tomography…

Researchers in the U.S. turned a special type of mouse stem cell into green, glowing lung cells in the lab and now have a limitless supply they can use as a model to study how pulmonary fibrosis and other lung diseases develop. “Our study has implications for the study…

Brilaroxazine, Reviva Pharmaceuticals’ experimental therapy for idiopathic pulmonary fibrosis (IPF), was found to reduce lung inflammation and fibrosis, or scarring, in a rat model of the disease. The treatment also improved lung function and extended survival in the animals, the study showed. Titled “Evaluation of Brilaroxazine (RP5063)…

An experimental oral medication Bristol Myers Squibb is developing did better than a placebo at slowing lung function decline for up to 26 weeks, slightly more than six months, in people with idiopathic pulmonary fibrosis (IPF). The effect was seen when the therapy, BMS-986278, was given at a…

Researchers have discovered a variant of the usual basal stem cells found in the lungs that may contribute to scarring, or fibrosis, in people with idiopathic pulmonary fibrosis (IPF) — and which may be a therapeutic target to slow disease progression. The team found that these basal stem cells,…

A high dose of bexotegrast, an oral treatment being developed by Pliant Therapeutics, continues to be well-tolerated for up to about nine months, with no serious side effects in people with idiopathic pulmonary fibrosis (IPF), according to long-term data from a Phase 2a trial. Six-month data from the…

AP02, an inhaled formulation of nintedanib being developed by Avalyn Pharma, was well tolerated by both healthy people and individuals with idiopathic pulmonary fibrosis (IPF) who took part in a Phase 1 clinical trial. The open-label study (ACTRN12620001141932) was designed to test the safety and tolerability…